What Standard ICC (A) Cargo Insurance Does Not Cover for Pharmaceutical Shipments

Institute Cargo Clauses (A) 2009 is the broadest standard cargo insurance form available on the London market and most international placements. It is all-risks cover, with named exclusions, and it forms the baseline for nearly every pharmaceutical cargo policy in Malaysia. The misunderstanding that catches NPRA-licensed importers at claim is the assumption that "all-risks" means "all losses". It does not. ICC (A) has named exclusions in Clauses 4 to 7, and several of those exclusions interact with pharmaceutical cargo losses in ways that standard general-cargo placements never need to address.

This guide itemises the named gaps in standard ICC (A) 2009 for pharmaceutical cargo, walks through the endorsements that close each gap, and sets out the placement-time conversation that turns a generic ICC (A) policy into one that responds to pharmaceutical losses. The primary reference is the Institute Cargo Clauses (A) 2009 wording itself, issued by the International Underwriting Association (IUA) and the Lloyd's Market Association (LMA).

Key Facts: What Standard ICC (A) Does Not Cover for Pharmaceutical Cargo

What is Institute Cargo Clauses (A) 2009? An all-risks cover form for cargo in transit, issued jointly by the International Underwriting Association and the Lloyd's Market Association, replacing the 1982 version. Clause 1 establishes all-risks cover for physical loss of or damage to the subject-matter insured. Clauses 4 to 7 set out specific exclusions. Clause 8 is the transit clause that defines when cover attaches and terminates.

What does Clause 4.3 of ICC (A) 2009 exclude? Loss or damage arising from insufficient or unsuitable packing or preparation of the subject-matter insured. For pharmaceutical cargo, this clause is the lever that lets an insurer argue that a failed passive temperature-controlled container or an inadequately pre-conditioned PCM constitutes a packing failure rather than a covered peril.

What does Clause 4.5 of ICC (A) 2009 exclude? Loss, damage, or expense proximately caused by delay, even though the delay is caused by a risk insured against. For pharmaceutical cargo with a limited shelf life or stability window, the delay exclusion is the most consequential exclusion in the base wording, and it requires explicit endorsement to close.

What does Clause 6 of ICC (A) 2009 exclude? War, civil war, revolution, rebellion, insurrection, capture, seizure, mines, torpedoes, and similar war risks. For pharmaceutical cargo on routes transiting Joint War Committee listed areas (Persian Gulf, Red Sea and Bab-el-Mandeb, Black Sea as of May 2026), war risk cover requires Institute War Clauses (Cargo) CL385 dated 01.01.2009 as a separate placement.

What does Clause 7 of ICC (A) 2009 exclude? Strikes, riots, civil commotions, and terrorism. Pharmaceutical cargo passing through ports or airports affected by strike action is exposed under this exclusion, with strikes cover available via Institute Strikes Clauses (Cargo) CL386 dated 01.01.2009.

What is the inherent vice exclusion at Clause 4.4? Loss or damage arising from inherent vice or nature of the subject-matter insured. For pharmaceutical cargo, the insurer can argue that loss arising from the product's stability profile (rather than from external causes) falls within inherent vice. The temperature deviation endorsement is what shifts the boundary so excursions caused by external causes are covered.

For the foundational explainer on the cover form, see Institute Cargo Clauses, the pharmaceutical imports cargo insurance cluster hub, and the Pharmaceutical & Medical Devices Cargo Insurance industry page.

Resource: Cargo Insurance Coverage Audit

Take the 9-question Cargo Insurance Coverage Audit to score your pharmaceutical cargo cover against the ICC (A) endorsement baseline. Free, no signup wall.

The Six Named Gaps in Standard ICC (A) for Pharmaceutical Cargo

Mapping the standard ICC (A) 2009 wording against pharmaceutical cargo realities produces six named gaps. Each is addressable through endorsement at placement.

Gap 1: Temperature Deviation Not in the Base Wording

ICC (A) covers physical loss of or damage to the subject-matter insured. Temperature excursion that renders pharmaceutical product unusable but leaves it physically intact does not fit neatly into "physical loss or damage" without additional contractual language. The base wording is not, on its own, a temperature-controlled cargo policy.

The endorsement that closes it: A temperature deviation endorsement, with the temperature range, the excursion trigger (combination of time and degrees), and the evidence standard explicitly written into the policy. The endorsement should be aligned to the registered product's stability data, not to a generic specification.

Gap 2: Reefer Equipment Breakdown

Mechanical or electrical failure of the refrigeration system during transit (compressor failure, refrigerant leak, electrical fault, power loss at transshipment) is not part of the ICC (A) base wording. Equipment breakdown is its own peril class that requires specific endorsement, particularly because failure can produce a temperature excursion that the base wording does not address even with a temperature deviation endorsement layered in.

The endorsement that closes it: A reefer equipment breakdown extension, covering loss or damage arising from mechanical or electrical failure of the refrigeration system during transit and at transshipment ports.

Gap 3: Delay Exclusion at Clause 4.5

Clause 4.5 of ICC (A) 2009 excludes loss, damage, or expense proximately caused by delay, even though the delay is caused by a risk insured against. For pharmaceutical cargo, delay-driven losses are a documented pattern: customs clearance delays, port congestion, vessel rerouting, transshipment hub backlog. The exclusion bites particularly hard on passive temperature-controlled shipments where the qualified hold-time can be exceeded by delays.

The endorsement that closes it: A specific delay endorsement, or language that addresses the interaction between the delay exclusion and the temperature deviation endorsement, so that a delay-caused excursion is treated as a covered peril rather than excluded.

Gap 4: Insufficient Packing at Clause 4.3

Clause 4.3 excludes loss or damage arising from insufficient or unsuitable packing or preparation of the subject-matter insured. For pharmaceutical cargo, this clause is the lever where an insurer can argue that a failed passive temperature-controlled container, an inadequately pre-conditioned PCM, or a packaging configuration not validated for the specific route, constitutes a packing failure rather than a covered peril.

The endorsement that closes it: Language that clarifies the policy's position on qualified passive container systems and pre-conditioned PCM. The placement-time conversation should specifically address whether validated and qualified passive systems are treated as fit packing under the policy.

Gap 5: Controlled Substances Sub-Limits or Exclusions

Standard pharmaceutical cargo policies frequently apply sub-limits to controlled substances under the Dangerous Drugs Act 1952 and Schedule 1 and Schedule 2 poisons under the Poisons Act 1952, or exclude them entirely unless a handling endorsement is purchased. The sub-limit or exclusion sits in the policy's commodity definitions or in specific clauses tied to controlled substance handling.

The endorsement that closes it: A controlled substances handling endorsement, with the scope explicitly written into the cover for Schedule 1 and Schedule 2 poisons and Dangerous Drugs Act 1952 controlled substances. Importers with mixed cargo (generics plus controlled analgesics, for example) need to review controlled substances scope at placement.

Gap 6: Regulatory Rejection

ICC (A) covers physical loss or damage in transit. Where a consignment arrives in physically intact condition but is rejected by NPRA, JKDM, or the importer's quality team for regulatory reasons (failed inspection, missing documentation, expired registration), the rejection is not a covered peril under the base wording. The financial consequence of rejection (re-export costs, destruction costs, market diversion) sits with the importer.

The endorsement that closes it: A rejection extension, covering the financial loss arising from regulatory rejection at the destination port. Rejection extensions are not universally available and the scope varies; the placement-time conversation determines what regulatory rejection scenarios are covered and what the recovery basis is.

How Each Gap Plays Out at Claim

For NPRA-licenced importers running ongoing pharmaceutical programmes, Marine Cargo Open Cover with the named endorsements above is the working placement structure; for one-off movements, Marine Cargo Insurance applies, and for high-value biologic and specialty consignments, Specialist High-Value Transit Insurance applies. For the industry view, see Pharmaceutical & Medical Devices Cargo Insurance.

The Standard ICC (A) 2009 Exclusion Set in Full

For reference, the full named exclusions in Institute Cargo Clauses (A) 2009 are:

• Clause 4.1. Loss, damage or expense attributable to wilful misconduct of the Assured.
• Clause 4.2. Ordinary leakage, ordinary loss in weight or volume, or ordinary wear and tear of the subject-matter insured.
• Clause 4.3. Loss, damage or expense caused by insufficiency or unsuitability of packing or preparation of the subject-matter insured (where packing or preparation is carried out prior to the attachment of cover, or by the Assured or their employees).
• Clause 4.4. Loss, damage or expense caused by inherent vice or nature of the subject-matter insured.
• Clause 4.5. Loss, damage or expense proximately caused by delay, even though the delay is caused by a risk insured against.
• Clause 4.6. Loss, damage or expense arising from insolvency or financial default of the owners, managers, charterers, or operators of the vessel.
• Clause 4.7. Loss or damage arising from the use of any weapon or device employing atomic or nuclear fission and similar.
• Clause 5. Unseaworthiness and unfitness of vessel, conveyance, container, or liftvan, where the Assured or their servants are privy to such unseaworthiness or unfitness at the time the subject-matter insured is loaded.
• Clause 6. War, civil war, revolution, rebellion, insurrection or civil strife arising therefrom, or any hostile act by or against a belligerent power.
• Clause 7. Strikes, locked-out workmen, persons taking part in labour disturbances, riots or civil commotions, and any act of terrorism or arising from political, ideological or religious motivation.

For pharmaceutical cargo, the load-bearing clauses are 4.3 (packing), 4.4 (inherent vice), 4.5 (delay), 5 (unseaworthiness for sea freight specifically), 6 (war), and 7 (strikes). The first three are addressed through pharmaceutical-specific endorsements; clauses 6 and 7 are addressed through separate war and strikes cover.

Standard ICC (A) is the baseline. The pharmaceutical-specific endorsements are where the policy actually responds.

Voyage arranges open cover marine cargo insurance for NPRA-licensed pharmaceutical importers with the six pharmaceutical-specific endorsements negotiated at placement. Request a coverage review at voyagecover.com/#contact-form or WhatsApp Kevin at +60 19 990 2450.

Mode-Specific Considerations Within the Base Cover

The base ICC (A) 2009 wording applies to all transit modes (sea, air, road, rail, multimodal), but the application differs by mode in ways that pharmaceutical cargo placements should address explicitly.

For air freight, the Montreal Convention 1999 carrier liability cap of 26 SDR per kilogramme of gross weight (effective 28 December 2024) sits underneath the ICC (A) policy. The Montreal Convention gap cover should be explicit in the policy, closing the gap between the carrier liability cap and the cargo's commercial value. Air freight scope should be explicitly written into the cover.

For sea freight, the Hague-Visby Rules cap (SDR 666.67 per package or 2 SDR per kilogramme, whichever is higher) sits underneath. The reefer equipment breakdown extension is the headline pharmaceutical-specific endorsement for sea freight, with the Hague-Visby cap as the carrier liability layer underneath. For the underlying convention, see Hague-Visby Rules.

For multimodal pharmaceutical shipments (origin warehouse to air carrier to ground handler to truck to bonded warehouse), the warehouse-to-warehouse transit clause at ICC (A) 2009 Clause 8 covers the entire chain in principle. The interaction between the different mode-specific carrier liability layers (Montreal for the air leg, Hague-Visby for any sea leg, CMR or local road carriage rules for trucking) sits beneath the cargo insurance policy.

The Placement-Time Checklist for Pharmaceutical ICC (A) Cover

For an NPRA-licensed importer reviewing or placing a pharmaceutical cargo policy, the placement-time conversation should specifically address each of the named gaps above.

• Temperature deviation: What temperature range and excursion trigger is written into the endorsement? Does it match the registered product's stability data?
• Reefer equipment breakdown: Is the extension in place? What is the trigger language? Does it cover transshipment power loss as well as in-transit equipment failure?
• Delay: How does the policy treat the interaction between Clause 4.5 (delay exclusion) and the temperature deviation endorsement? Is there a delay endorsement?
• Packing: How does the policy treat qualified passive container systems? Is there clarification language that prevents the Clause 4.3 packing exclusion from being asserted against validated passive packaging?
• Controlled substances: Is there a controlled substances handling endorsement? What is the scope (Schedule 1 and Schedule 2 poisons, Dangerous Drugs Act 1952 controlled substances)? What sub-limits apply?
• Regulatory rejection: Is a rejection extension available? What scenarios does it cover (NPRA rejection, JKDM rejection, importer's quality team rejection)? What does it pay (re-export costs, destruction costs, cargo value)?
• Air freight scope: Is air freight explicitly covered? Is Montreal Convention gap cover endorsed?
• War and strikes: Are Institute War Clauses (Cargo) CL385 and Institute Strikes Clauses (Cargo) CL386 in place for the relevant corridors?
• Inherent vice: How does the policy treat the boundary between inherent vice (Clause 4.4) and externally-caused damage for biologic cargo?
• Documentation conditions: What documentation does the policy treat as a claims condition? Are the conditions realistic against the operations team's handover process? See the related cluster article on GDP documentation and cargo insurance claims.

Why Not Buy Cheaper ICC (B) or ICC (C) for Pharmaceutical Cargo?

Pharmaceutical importers occasionally ask whether the narrower ICC (B) or ICC (C) named-perils forms could work for their cargo at lower cost. The answer is: rarely.

ICC (B) 2009 is named perils only. The named perils are fire, explosion, vessel stranding or sinking or capsizing, overturning or derailment of land conveyance, collision, discharge of cargo at a port of distress, jettison, washing overboard, entry of sea, lake, or river water into the vessel or conveyance or container, and total loss of any package lost overboard or dropped whilst loading or unloading. ICC (B) does not cover theft, pilferage, contamination, or temperature deviation. For pharmaceutical cargo, ICC (B) is rarely fit for purpose.

ICC (C) 2009 is the most restrictive named-perils form. The named perils are limited to fire, explosion, vessel stranding or sinking or capsizing, overturning or derailment of land conveyance, collision, discharge at a port of distress, jettison, and general average sacrifice. ICC (C) does not cover theft, washing overboard, water entry, or most water damage. For pharmaceutical cargo, ICC (C) is functionally inadequate, which is why Incoterms 2020 upgraded CIP to require ICC (A) minimum.

The reason CIF still requires only ICC (C) minimum under Incoterms 2020 is a relic of the original convention. For pharmaceutical CIF imports, the practical position is that the importer should purchase top-up cover to bring the insurance scope to ICC (A) with the six pharmaceutical-specific endorsements outlined above.

Frequently Asked Questions

Is Institute Cargo Clauses (A) 2009 the broadest cargo insurance available?

Yes, it is the broadest standard ICC form, providing all-risks cover for physical loss or damage to cargo in transit subject to the named exclusions in Clauses 4 to 7. Broader cover is available through specific extensions and endorsements layered on top, particularly for pharmaceutical cargo where the standard wording has known gaps.

What is the most consequential ICC (A) exclusion for pharmaceutical cargo?

Clause 4.5, the delay exclusion. Delay-caused excursions (customs clearance delays, port congestion, transshipment hub backlog, vessel rerouting) are a documented loss pattern for pharmaceutical cargo with limited shelf life or hold-time tolerance. The exclusion bites unless specifically endorsed.

Does ICC (A) cover temperature deviation directly?

Not in its base wording. ICC (A) covers physical loss or damage; temperature excursion that renders product unusable but leaves it physically intact is treated as deterioration rather than as a covered peril unless a temperature deviation endorsement is written into the policy.

Does ICC (A) cover reefer equipment breakdown?

Not in its base wording. Mechanical or electrical failure of the refrigeration system during transit typically falls outside the standard wording unless a reefer equipment breakdown extension is endorsed. For pharmaceutical sea reefer cargo, the extension is one of the foundational endorsements.

What is the Clause 4.3 packing exclusion and how does it affect pharmaceutical cargo?

Clause 4.3 excludes loss or damage arising from insufficient or unsuitable packing or preparation, where packing is carried out prior to attachment of cover or by the assured. For pharmaceutical cargo, the clause is the lever where an insurer can argue that a failed passive temperature-controlled container or an inadequately pre-conditioned PCM is a packing failure rather than a covered peril. Clarification language at placement is the fix.

Does ICC (A) cover regulatory rejection at the destination port?

Not by default. ICC (A) covers physical loss or damage in transit. Regulatory rejection of a physically intact consignment by NPRA or JKDM is not a covered peril under the base wording. A rejection extension can be added at placement, with scope varying by insurer.

Are war and strikes risks covered under ICC (A)?

No. Clauses 6 and 7 of ICC (A) 2009 exclude war and strikes risks respectively. Cover is available through separate placements: Institute War Clauses (Cargo) CL385 dated 01.01.2009 for war risk and Institute Strikes Clauses (Cargo) CL386 dated 01.01.2009 for strikes. Both are commonly placed alongside the ICC (A) base cover.

Why not buy ICC (C) for pharmaceutical cargo if it is cheaper?

ICC (C) is the most restrictive named-perils form, covering only fire, explosion, vessel stranding, collision, discharge at port of distress, jettison, and general average sacrifice. It does not cover theft, water entry, washing overboard, contamination, or temperature deviation. For pharmaceutical cargo, ICC (C) is functionally inadequate, which is why Incoterms 2020 upgraded CIP to require ICC (A) minimum. ICC (B) sits between (C) and (A) but is also rarely fit for pharmaceutical cargo.

Voyage Conclusion

Institute Cargo Clauses (A) 2009 is the baseline for pharmaceutical cargo insurance, but the baseline is not the full policy. The named exclusions in Clauses 4 to 7 produce six load-bearing gaps for pharmaceutical cargo: temperature deviation, reefer equipment breakdown, delay, packing, controlled substances sub-limits, and regulatory rejection. Closing each gap is the placement-time conversation.

Talk to Voyage about Marine Cargo Open Cover for NPRA-licenced pharmaceutical importers with the six pharmaceutical-specific endorsements negotiated at placement. For high-value transits, Specialist High-Value Transit Insurance applies. For the industry view, see Pharmaceutical & Medical Devices Cargo Insurance. WhatsApp +60 19 990 2450 or use the contact form.

Take the Cargo Insurance Coverage Audit

Score your pharmaceutical cargo programme: Cargo Insurance Coverage Audit. Free, no signup wall.

Related in the pharmaceutical cluster: pharmaceutical imports cargo insurance cluster hub, temperature excursion pharmaceutical liability, GDP compliance and cargo insurance, plus the broader foundational guides: Institute Cargo Clauses and LC insurance certificate requirements.

Disclaimer: This article provides general guidance on Institute Cargo Clauses (A) 2009 exclusions and pharmaceutical-specific endorsements as of May 2026. Policy wordings, exclusion interpretations, and endorsement scope vary materially between insurers; the specific wording of any given placement should be reviewed line by line before placement.

Coverage terms, conditions, and availability vary by insurer, policy, and jurisdiction. Always review your specific policy wording and consult a qualified insurance or legal professional before making coverage decisions.